PLG and freckles: Its’ first documented dermatological application was in 1979 by Sadako from Japan who observed a significant reduction in melasma severity within 2 weeks.12 TA is a synthetic lysine analogue with antifibrinolytic activity that hinders paracrine melanogenic mediators which induce melanocytes synthesis and has historically been used to prevent haemorrhagic episodes.13 Furthermore, TA competitively binds to the lysine-site of plasminogen, thereby inhibiting its conversion to plasmin and stabilizing the fibrin matrix.